{"id":4284,"date":"2026-08-13T05:04:59","date_gmt":"2026-08-13T05:04:59","guid":{"rendered":"https:\/\/education.mirrorplasticsurgery.com\/uncategorized\/semaglutide-lab-monitoring\/"},"modified":"2026-09-09T05:16:27","modified_gmt":"2026-09-09T05:16:27","slug":"semaglutide-lab-monitoring","status":"publish","type":"post","link":"https:\/\/www.mirrorplasticsurgery.com\/education\/peptides\/semaglutide-lab-monitoring","title":{"rendered":"Semaglutide Lab Monitoring: A Guide to GLP-1 Blood Tests"},"content":{"rendered":"<p><em>Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026<\/em><\/p>\n<h2 id=\"key-takeaways\">Key Takeaways on Semaglutide Lab Monitoring<\/h2>\n<ul>\n<li>Semaglutide affects the whole metabolic system, so monitoring focuses on organ function, blood sugar, lipids, and nutrition rather than drug levels.<\/li>\n<li>Baseline labs should include HbA1c, a comprehensive metabolic panel, a fasting lipid panel, TSH, and pregnancy testing to confirm safety and create reference points.<\/li>\n<li>Most stable patients follow a 3-6-12 month lab schedule in the first year, with closer monitoring for chronic kidney disease and other risk factors.<\/li>\n<li>New or severe symptoms such as intense abdominal pain, dehydration, or persistent vomiting call for urgent, targeted testing to rule out pancreatitis, gallbladder disease, or acute kidney injury.<\/li>\n<li>At Mirror Plastic Surgery, Dr. Akash Chandawarkar builds individualized semaglutide monitoring plans around each patient\u2019s lab results and physiology.<\/li>\n<\/ul>\n<h2>Baseline Blood Tests Before Starting Semaglutide<\/h2>\n<p><a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">Baseline laboratory assessment forms the foundation of safe pharmacotherapy<\/a>. The following tests are recommended before you begin treatment:<\/p>\n<ul>\n<li><strong>Hemoglobin A1c (HbA1c):<\/strong> Documents average blood sugar control over the prior 2\u20133 months and sets the baseline for tracking glycemic response. <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">Clinical trial data from the SUSTAIN program showed that semaglutide can lower A1c by an average of 1.0\u20131.8 percentage points depending on dose and baseline.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li><strong>Comprehensive Metabolic Panel (CMP):<\/strong> Evaluates kidney markers (creatinine, BUN, eGFR), liver enzymes (ALT, AST, ALP, bilirubin), electrolytes, and glucose. These values establish organ health before treatment and help interpret any later changes.<\/li>\n<li><strong>Fasting Lipid Panel:<\/strong> <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">GLP-1 therapy and weight loss can improve lipid markers, so pretreatment values are needed to measure benefit.<\/a> <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">Data from the SUSTAIN and SCALE trials showed reductions in LDL cholesterol, total cholesterol, and triglycerides with modest HDL increases.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/li>\n<li><strong>Thyroid-Stimulating Hormone (TSH):<\/strong> <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">TSH helps identify thyroid disease that could affect weight or metabolic response.<\/a> <a href=\"https:\/\/healthrx.com\/wegovy\/safety-signals-fda\" target=\"_blank\" rel=\"noindex nofollow\">Semaglutide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2).<\/a><\/li>\n<li><strong>Pregnancy Test:<\/strong> <a href=\"https:\/\/healthrx.com\/wegovy\/special-populations\" target=\"_blank\" rel=\"noindex nofollow\">Wegovy is contraindicated in pregnancy<\/a>, and the FDA label advises stopping it at least two months before a planned pregnancy because of the drug\u2019s long half-life.<\/li>\n<\/ul>\n<p>Additional tests such as lipase, amylase, and calcitonin <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">are clinically reasonable for patients with a history of pancreatitis, cholelithiasis, hypertriglyceridemia, heavy alcohol use, thyroid nodules, neck radiation, or a family history of thyroid cancer<\/a>, but clinicians do not universally require them. As Dr. Singh explains, <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">\u201cPrescribing without a baseline laboratory picture is the equivalent of overhauling a complex engine without first running diagnostics.\u201d<\/a><\/p>\n<h2>Routine Monitoring Schedule During Semaglutide Therapy<\/h2>\n<p><a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">Stable patients typically follow a 3-6-12 month monitoring cadence during the first year, with HbA1c, a fasting lipid panel, and a comprehensive metabolic panel drawn at each interval.<\/a> After the first year, many stable patients can move to testing every 6 to 12 months.<\/p>\n<table>\n<thead>\n<tr>\n<th>Test<\/th>\n<th>When<\/th>\n<th>Why<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>HbA1c<\/td>\n<td><a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">Every 3 months (first year), then every 6 months<\/a><\/td>\n<td><a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">Tracks glycemic response based on the A1c reduction described earlier<\/a><\/td>\n<\/tr>\n<tr>\n<td>Comprehensive Metabolic Panel<\/td>\n<td><a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">Every 3\u20136 months<\/a><\/td>\n<td>Monitors kidney and liver function and detects dehydration-related kidney stress.<\/td>\n<\/tr>\n<tr>\n<td>Fasting Lipid Panel<\/td>\n<td><a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">At 3 months, then annually<\/a><\/td>\n<td>Documents changes in cholesterol and triglycerides.<\/td>\n<\/tr>\n<tr>\n<td>TSH<\/td>\n<td><a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">Annually<\/a><\/td>\n<td>Provides ongoing thyroid surveillance per Endocrine Society guidance.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">Routine lipase screening is not recommended in asymptomatic patients because elevated lipase without symptoms is common and does not predict clinical pancreatitis.<\/a> Patients with <a href=\"https:\/\/meto.co\/blog\/glp1-lab-work-questions-doctor-semaglutide\" target=\"_blank\" rel=\"noindex nofollow\">an eGFR below 60 mL\/min\/1.73m\u00b2 need more frequent monitoring<\/a>. For those with CKD stage 3 or higher, <a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">intensified renal surveillance includes a basic metabolic panel at every dose-escalation step and at 1, 3, 6, 9, and 12 months on maintenance therapy.<\/a><\/p>\n<p>Given this level of testing, many patients wonder whether the medication itself appears on any of these panels. It does not, as explained below.<\/p>\n<h2>Semaglutide and Bloodwork Detection<\/h2>\n<p><strong>No.<\/strong> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Standard blood tests do not detect semaglutide or other GLP-1 drugs, and they do not appear on routine blood panels, drug screens, or workplace testing.<\/a> Monitoring focuses on metabolic and organ health, reflecting how the body responds to the medication rather than detecting the drug itself. The impact of semaglutide appears indirectly through improved HbA1c, lower triglycerides, and changes in liver enzymes.<\/p>\n<h2>Symptom-Driven Testing Beyond Routine Labs<\/h2>\n<p>Certain symptoms call for immediate laboratory evaluation instead of waiting for the next scheduled draw. The following approach reflects current FDA guidance and clinical evidence:<\/p>\n<ul>\n<li><strong>Severe abdominal pain radiating to the back with nausea or vomiting:<\/strong> Order lipase and amylase to rule out pancreatitis. <a href=\"https:\/\/healthrx.com\/wegovy\/safety-signals-fda\" target=\"_blank\" rel=\"noindex nofollow\">FDA guidance recommends discontinuing semaglutide if pancreatitis is suspected and avoiding reinitiation if confirmed.<\/a> <a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">A lipase level more than three times the upper limit of normal with consistent symptoms warrants discontinuation and standard pancreatitis management.<\/a><\/li>\n<li><strong>Right upper quadrant pain:<\/strong> Check liver function tests and consider gallbladder ultrasound. <a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">In the STEP trials, cholelithiasis occurred in 1.6% of semaglutide-treated patients versus 0.7% on placebo.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> <a href=\"https:\/\/guidelinecentral.com\/drug\/ee06186f-2aa3-4990-a760-757579d8f77b\" target=\"_blank\" rel=\"noindex nofollow\">The Wegovy prescribing information notes a higher incidence of acute gallbladder disease in semaglutide-treated patients even after adjusting for weight loss.<\/a><\/li>\n<li><strong>Decreased urine output, dizziness, or persistent vomiting beyond 72 hours:<\/strong> Check creatinine and eGFR. <a href=\"https:\/\/healthrx.com\/wegovy\/safety-signals-fda\" target=\"_blank\" rel=\"noindex nofollow\">Post-marketing reports link semaglutide to acute kidney injury, usually in the setting of severe dehydration from vomiting and diarrhea.<\/a> <a href=\"https:\/\/healthrx.com\/wegovy\/monitoring-schedule\" target=\"_blank\" rel=\"noindex nofollow\">A rise in serum creatinine of 0.3 mg\/dL or more from baseline, or a drop in eGFR of 25% or more, should prompt temporary dose reduction and assessment for IV hydration.<\/a><\/li>\n<li><strong>Persistent vomiting or very poor oral intake:<\/strong> Consider thiamine (vitamin B1) testing. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70256\" target=\"_blank\" rel=\"noindex nofollow\">A 2026 systematic review identified six cases of Wernicke\u2019s encephalopathy after semaglutide treatment, all involving prolonged gastrointestinal symptoms and substantial weight loss before neurological decline.<\/a> When Wernicke\u2019s encephalopathy is suspected, clinicians should administer high-dose parenteral thiamine immediately without waiting for lab confirmation.<\/li>\n<\/ul>\n<h2>Liver Enzyme Changes on Semaglutide<\/h2>\n<p>Semaglutide is not hepatotoxic; clinical evidence shows that it actually reduces liver enzymes. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13420891\" target=\"_blank\" rel=\"noindex nofollow\">A 2026 meta-analysis in the British Journal of Clinical Pharmacology that included 10 studies (n=1,908) found significant reductions in serum AST (WMD \u22128.54 U\/L; p&lt;0.00001) and ALT (WMD \u221215.84 U\/L; p&lt;0.00001) compared with controls.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> In the SELECT trial, <a href=\"https:\/\/nature.com\/articles\/s41591-026-04281-1\" target=\"_blank\" rel=\"noindex nofollow\">semaglutide 2.4 mg produced statistically significant relative reductions versus placebo at week 104: ALT by 6%, AST by 3%, and GGT by 17%, all with P &lt; 0.0001.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup><\/p>\n<p>Mild, transient elevations up to twice the upper limit of normal <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">can appear in the first three months during rapid weight loss because of increased hepatic fatty acid flux<\/a>. These changes usually resolve. Sustained elevations above three times the upper limit of normal warrant further evaluation. <a href=\"https:\/\/frontiersin.org\/journals\/medicine\/articles\/10.3389\/fmed.2026.1783429\/full\" target=\"_blank\" rel=\"noindex nofollow\">Semaglutide has conditional FDA approval for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.<\/a><\/p>\n<h2>Nutritional Monitoring for B12, Iron, and Other Deficiencies<\/h2>\n<p><a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Up to 40% of weight lost on GLP-1 drugs can be lean mass.<\/a><sup data-disclaimer-id=\"6\" data-disclaimer-index=\"1\">1<\/sup> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13316283\" target=\"_blank\" rel=\"noindex nofollow\">Diets that provide fewer than roughly 1,200 kcal per day in women or 1,800 kcal per day in men may struggle to meet micronutrient needs without targeted planning.<\/a> This pattern matters because semaglutide often reduces caloric intake by 30\u201350%. The following markers deserve periodic review:<\/p>\n<ul>\n<li><strong>Vitamin B12:<\/strong> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Delayed gastric emptying can impair B12 absorption over time, and metformin use increases this risk.<\/a><\/li>\n<li><strong>Iron (ferritin, transferrin saturation):<\/strong> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Lower food intake and reduced red meat consumption raise deficiency risk, especially in women who also have menstrual blood loss.<\/a><\/li>\n<li><strong>Vitamin D:<\/strong> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Vitamin D is fat-soluble and stored in body fat, so rapid fat loss can briefly raise levels before they fall; long-term users often see levels decline after the initial weight-loss phase.<\/a><\/li>\n<li><strong>Folate:<\/strong> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Lower intake of leafy greens and legumes directly reduces folate intake, and deficiency can cause fatigue, irritability, and megaloblastic anemia.<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC13316283\" target=\"_blank\" rel=\"noindex nofollow\">Micronutrient testing during GLP-1 therapy should be guided by symptoms and risk factors rather than a universal panel.<\/a> High-risk groups include patients with prior bariatric surgery, gastrointestinal disorders, poor baseline diet quality, older age, or prolonged nausea and vomiting. Testing at baseline, at 3 months, and then every 6 months is reasonable, with earlier testing if symptoms such as fatigue, hair shedding, or cognitive fog appear.<\/p>\n<p><a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Schedule a consultation to review your nutritional labs<\/a> and align them with your semaglutide plan.<\/p>\n<h2>Compounded Semaglutide Monitoring Considerations<\/h2>\n<p><a href=\"https:\/\/healthrx.com\/wegovy\/safety-signals-fda\" target=\"_blank\" rel=\"noindex nofollow\">The FDA has issued multiple safety communications explaining that compounded semaglutide products are not FDA-approved and may carry risks related to formulation quality, sterility, and dosing accuracy.<\/a> <a href=\"https:\/\/helvy.co.uk\/guides\/ozempic-blood-tests\" target=\"_blank\" rel=\"noindex nofollow\">Compounded semaglutide acts through the same mechanism and requires the same monitoring as branded semaglutide<\/a>, so the full baseline and follow-up protocol in this guide still applies. Because compounded products lack FDA oversight, medical supervision becomes even more critical.<\/p>\n<p>Mirror Plastic Surgery sources peptides from reputable providers with batch testing and designs protocols around each patient\u2019s labs and physiology. The practice also offers newer-generation options such as GLP-3R, which early reports associate with fewer gastrointestinal side effects and broader indications including insulin resistance and cardiovascular risk factors. The same baseline and follow-up monitoring framework applies to these therapies.<\/p>\n<h2>How to Talk to Your Doctor About Lab Monitoring<\/h2>\n<p>Patients who understand their monitoring plan can spot problems sooner and advocate for appropriate care. Consider asking your prescribing provider questions such as:<\/p>\n<ul>\n<li>\u201cWhat baseline labs are you ordering before I start semaglutide?\u201d<\/li>\n<li>\u201cHow often will I need follow-up blood work, and which tests will you run?\u201d<\/li>\n<li>\u201cWhat symptoms should prompt earlier lab testing?\u201d<\/li>\n<li>\u201cCan you walk me through what my results mean for my treatment?\u201d<\/li>\n<\/ul>\n<h2>About Mirror Plastic Surgery\u2019s Semaglutide and Peptide Care<\/h2>\n<p>Mirror Plastic Surgery is a concierge practice serving the St. Petersburg and Tampa Bay area of Florida. Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon with fellowship training in aesthetic surgery and medical innovation training at Stanford, personally oversees all peptide and GLP-1 therapy protocols. As a board-certified physician, he designs each protocol around the patient\u2019s labs, physiology, and goals.<\/p>\n<figure style=\"text-align: center\"><a href=\"https:\/\/www.mirrorplasticsurgery.com\/about-us\/dr.-akash-chandawarkar\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/cdn.aigrowthmarketer.co\/1788902121774-3fcf2fc7e0ba.webp\" alt=\"Dr. Akash, Board-Certified Plastic Surgeon\" style=\"max-height: 500px\" loading=\"lazy\"><\/a><figcaption><em>Dr. Akash, Board-Certified Plastic Surgeon<\/em><\/figcaption><\/figure>\n<p>The practice typically reserves up to an hour per consultation, performs detailed lab analysis, and offers 24\/7 direct text access to Dr. Chandawarkar. This level of concierge oversight contrasts with high-volume telehealth platforms that often prescribe without baseline testing or ongoing monitoring. Mirror Plastic Surgery provides semaglutide, GLP-3R, and a full range of personalized peptide stacks, each tailored to the patient\u2019s individual results.<\/p>\n<p><a href=\"https:\/\/www.mirrorplasticsurgery.com\/consultation\" target=\"_blank\">Request your personalized monitoring protocol<\/a> and begin physician-supervised semaglutide or peptide therapy.<\/p>\n<h2>The Bottom Line on Semaglutide Lab Monitoring<\/h2>\n<p>Semaglutide is a powerful metabolic medication that works best with personalized, physician-guided lab monitoring. Baseline testing defines your starting point. Routine follow-up every 3\u20136 months tracks how your body responds. Symptom-driven testing helps catch rare but serious complications such as pancreatitis, gallbladder disease, acute kidney injury, and thiamine deficiency before they progress.<\/p>\n<p>Monitoring should match your risk profile, comorbidities, and treatment goals rather than follow a one-size-fits-all template. If you are considering semaglutide or already taking it without structured medical oversight, work with a qualified provider who will build a monitoring plan around your unique physiology.<\/p>\n<p><em>This article is for educational purposes only and does not replace professional medical advice. Individual monitoring protocols vary based on medical history, risk factors, and treatment goals. Always consult a qualified healthcare provider before starting or adjusting any medication.<\/em><\/p>\n<hr data-disclaimer-divider=\"true\">\n<div data-disclaimer-footer=\"true\">\n<p data-disclaimer-id=\"6\" data-disclaimer-type=\"content_based\"><sup data-disclaimer-index=\"1\">1<\/sup> Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.<\/p>\n<p data-disclaimer-id=\"5\" data-disclaimer-type=\"fixed\">Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.<\/p>\n<\/div>\n<section data-read-next=\"true\">\n<h2>Read Next<\/h2>\n<ul>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/semaglutide-weight-loss-labs\" target=\"_blank\">Semaglutide Weight Loss Labs: A Practical Monitoring Guide<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/glp1-lab-monitoring-schedule\" target=\"_blank\">GLP-1 Lab Monitoring: What Blood Tests You Need<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/safe-semaglutide-administration-guidelines\" target=\"_blank\">Safe Semaglutide Administration Guidelines for Weight Loss<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/semaglutide-side-effects-management\" target=\"_blank\">Managing Semaglutide Side Effects Safely: A Complete Guide<\/a><\/li>\n<li><a href=\"https:\/\/education.mirrorplasticsurgery.com\/peptides\/semaglutide-peptide-therapy-reviews\" target=\"_blank\">Honest Semaglutide Peptide Therapy Reviews for Weight Loss<\/a><\/li>\n<\/ul>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Learn which blood tests to get before and during semaglutide therapy. Mirror Plastic Surgery provides expert GLP-1 monitoring and personalized care.<\/p>\n","protected":false},"author":21,"featured_media":4283,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-4284","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/4284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/comments?post=4284"}],"version-history":[{"count":1,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/4284\/revisions"}],"predecessor-version":[{"id":4999,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/posts\/4284\/revisions\/4999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/media\/4283"}],"wp:attachment":[{"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/media?parent=4284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/categories?post=4284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mirrorplasticsurgery.com\/education\/wp-json\/wp\/v2\/tags?post=4284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}